Format

Send to

Choose Destination
Inflamm Bowel Dis. 2011 Jul;17(7):1603-9. doi: 10.1002/ibd.21488. Epub 2010 Nov 4.

Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review.

Author information

1
Pediatric Gastroenterology, Hepatology, and Nutrition, Lucile Packard Children's Hospital, Stanford University Medical Center, Stanford, California, CA, USA. ktpark@stanford.edu

Abstract

The United States spends more for healthcare than any other country in the world. With the rising prevalence of both Crohn's disease and ulcerative colitis, inflammatory bowel disease (IBD) represents the leading chronic gastrointestinal disease with increasing healthcare expenditures in the US. IBD costs have shifted from inpatient to outpatient care since the introduction of biologic therapies as the standard of care. Gastroenterologists need to be aware of the national cost burden of IBD and clinical practices that optimize cost-efficiency. This investigation offers a systematic review of the economics of IBD and evidence-based strategies for cost-effective management.

PMID:
21053357
DOI:
10.1002/ibd.21488
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center